Beximco Pharmaceuticals Ltd Beximco Pharma commences export to Kuwait (5122B)
17 June 2016 - 4:00PM
UK Regulatory
TIDMBXP
RNS Number : 5122B
Beximco Pharmaceuticals Ltd
17 June 2016
BEXIMCO PHARMACEUTICALS LTD.
17 June, 2016
Beximco Pharma commences export to Kuwait
First time a Bangladeshi pharmaceutical company has launched
pharmaceutical products in any Gulf member country
Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or
"Company"), the fast-growing manufacturer of generic pharmaceutical
products and active pharmaceutical ingredients, announces that it
has commenced the export of pharmaceuticals to Kuwait. This marks
the first time a Bangladeshi pharmaceutical company has launched
pharmaceutical products in any Gulf member country under the Gulf
Cooperation Council (GCC).
A launch ceremony was held at Beximco Pharma's factory in Dhaka
to mark the shipment of the first consignment to Kuwait in the
presence of the Ambassador of Kuwait, His Excellency Mr. Adel
Mohammad A. H Hayat.
Initial exports to Kuwait from Beximco Pharma include two
metered-dose inhaler products for asthma and other respiratory
conditions, namely Azmasol (Salbutamol), Bexitrol-F (Salmeterol
plus Fluticasone) and one blood pressure drug Amdocal (Amlodipine).
The Company expects to launch additional products in Kuwait later
this year. We estimate the combined Gulf market to be worth USD 9
Billion and the Kuwait market alone to be worth USD 1.5
Billion.
Managing Director of Beximco Pharma, Nazmul Hassan MP,
commented:
"Beximco Pharma continues to build its presence in emerging and
developed markets. The Company is increasingly focused on regulated
markets, such as the US, EU, GCC and Australia, where the demand
for generic pharmaceutical products is rising. The Gulf market is
an important market for us and the launch of our products in Kuwait
will open up new opportunities in the region. We will continue to
expand our product range in the Gulf market, providing patients
with safe and affordable treatment options."
Beximco Pharma is the largest exporter of pharmaceuticals in
Bangladesh, winning the country's National Export Trophy a record
five times, the highest national accolade for export. The Company
currently has a global footprint in more than 50 countries and has
been accredited by a number of global regulatory authorities,
including the US FDA, AGES (EU), TGA Australia, Health Canada, GCC
and TFDA.
For further information please visit www.beximcopharma.com or
enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Sean Wyndham-Quin
Tel: +44 (0)20 3368 3551 / 3555
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma
manufactures and sells generic pharmaceutical formulation products
and active pharmaceutical ingredients. The Company also undertakes
contract manufacturing for multinational and leading global generic
pharmaceutical companies. The Company operates from a 23 acre site
in Dhaka and has manufacturing facilities for producing various
drugs in different delivery systems such as tablets, capsules,
liquids, semi-solids, intravenous fluids, metered dose inhalers,
dry powder inhalers, sterile ophthalmic drops, prefilled syringes,
injectables, nebulizer solutions, oral soluble films etc. Ensuring
access to quality medicines is the powerful aspiration that
motivates 3,000 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are
certified by global regulatory authorities of USA, Australia,
Europe, Latin America, and Canada, among others. The Company's
products are sold to retail outlets, medical institutions and other
pharmaceutical manufacturers in Bangladesh, in regional markets
such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and
in other markets overseas, principally in Africa, including South
Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria;
Pacific Island; Latin and Central American countries; Middle East;
Central Asia, including Azerbaijan; South East Asia, including
Singapore, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong;
Europe, including Austria, Germany and Romania; Australia etc.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEASKXFAXKEEF
(END) Dow Jones Newswires
June 17, 2016 02:00 ET (06:00 GMT)
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From Apr 2024 to May 2024
Beximco Pharma (LSE:BXP)
Historical Stock Chart
From May 2023 to May 2024